Latest Rosetta Genomics Stories
LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB).
PHILADELPHIA and REHOVOT, Israel, July 6, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital.
PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California, Davis ("UC Davis" or the "University") to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy.
PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
PHILADELPHIA and REHOVOT, Israel, April 12, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) today announced that the Company's Board of Directors has appointed Director Brian A.
Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis (BM).
FREMONT, Calif., March 29, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc.
MircoRNAâ€™s are making the diagnosis and treatment of lung cancer faster and more precise.
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
HAYWARD, Calif., Aug. 10 /PRNewswire/ -- Advanced Cell Diagnostics, Inc.